http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 05 Jan 2026 16:51:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++CYBIN+INC.++++++++++++++++For%3A+Jan+05/25806172.html si-local-file:///var/storage/secattach/20260105/25806172.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++CYBIN+INC.++++++++++++++++For%3A+Jan+05/25806172.html Mon, 05 Jan 2026 16:51:00 -0500 CYBN HELP O.37286706 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++CYBIN+INC.++++++++++++++++For%3A+Jan+05/25806172.html si-local-file:///var/storage/secattach/20260105/25806172.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++CYBIN+INC.++++++++++++++++For%3A+Jan+05/25806172.html Mon, 05 Jan 2026 16:51:00 -0500 CYBN HELP O.37286706 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++CYBIN+INC.++++++++++++++++For%3A+Jan+05/25806172.html si-local-file:///var/storage/secattach/20260105/25806172.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++CYBIN+INC.++++++++++++++++For%3A+Jan+05/25806172.html Mon, 05 Jan 2026 16:51:00 -0500 CYBN HELP O.37286706 http://www.streetinsider.com/Press+Releases/HELUS+Pharma+Propels+Therapeutic+Innovation+in+Mental+Health+and+Commences+Trading+on+Nasdaq/25801295.html <ul class="bwlistdisc"> <li> Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company </li> <li> Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP </li> <li> Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 </li> <li> Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been http://www.streetinsider.com/Press+Releases/HELUS+Pharma+Propels+Therapeutic+Innovation+in+Mental+Health+and+Commences+Trading+on+Nasdaq/25801295.html Mon, 05 Jan 2026 07:30:00 -0500 A.06822034 A.17150087 CYBN HELP HELP O.20026344 O.37286706 O.49223070 http://www.streetinsider.com/Press+Releases/HELUS+Pharma+Propels+Therapeutic+Innovation+in+Mental+Health+and+Commences+Trading+on+Nasdaq/25801295.html <ul class="bwlistdisc"> <li> Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company </li> <li> Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP </li> <li> Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 </li> <li> Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been http://www.streetinsider.com/Press+Releases/HELUS+Pharma+Propels+Therapeutic+Innovation+in+Mental+Health+and+Commences+Trading+on+Nasdaq/25801295.html Mon, 05 Jan 2026 07:30:00 -0500 A.06822034 A.17150087 CYBN HELP HELP O.20026344 O.37286706 O.49223070 http://www.streetinsider.com/Press+Releases/HELUS+Pharma+Propels+Therapeutic+Innovation+in+Mental+Health+and+Commences+Trading+on+Nasdaq/25801295.html <ul class="bwlistdisc"> <li> Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company </li> <li> Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP </li> <li> Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 </li> <li> Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been http://www.streetinsider.com/Press+Releases/HELUS+Pharma+Propels+Therapeutic+Innovation+in+Mental+Health+and+Commences+Trading+on+Nasdaq/25801295.html Mon, 05 Jan 2026 07:30:00 -0500 A.06822034 A.17150087 CYBN HELP HELP O.20026344 O.37286706 O.49223070 http://www.streetinsider.com/Press+Releases/HELUS+Pharma+Propels+Therapeutic+Innovation+in+Mental+Health+and+Commences+Trading+on+Nasdaq/25801295.html <ul class="bwlistdisc"> <li> Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company </li> <li> Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP </li> <li> Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 </li> <li> Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been http://www.streetinsider.com/Press+Releases/HELUS+Pharma+Propels+Therapeutic+Innovation+in+Mental+Health+and+Commences+Trading+on+Nasdaq/25801295.html Mon, 05 Jan 2026 07:30:00 -0500 A.06822034 A.17150087 CYBN HELP HELP O.20026344 O.37286706 O.49223070 http://www.streetinsider.com/Press+Releases/HELUS+Pharma+Propels+Therapeutic+Innovation+in+Mental+Health+and+Commences+Trading+on+Nasdaq/25801295.html <ul class="bwlistdisc"> <li> Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company </li> <li> Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP </li> <li> Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 </li> <li> Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been http://www.streetinsider.com/Press+Releases/HELUS+Pharma+Propels+Therapeutic+Innovation+in+Mental+Health+and+Commences+Trading+on+Nasdaq/25801295.html Mon, 05 Jan 2026 07:30:00 -0500 A.06822034 A.17150087 CYBN HELP HELP O.20026344 O.37286706 O.49223070 http://www.streetinsider.com/Press+Releases/HELUS+Pharma+Propels+Therapeutic+Innovation+in+Mental+Health+and+Commences+Trading+on+Nasdaq/25801295.html <ul class="bwlistdisc"> <li> Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company </li> <li> Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP </li> <li> Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 </li> <li> Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been http://www.streetinsider.com/Press+Releases/HELUS+Pharma+Propels+Therapeutic+Innovation+in+Mental+Health+and+Commences+Trading+on+Nasdaq/25801295.html Mon, 05 Jan 2026 07:30:00 -0500 A.06822034 A.17150087 CYBN HELP HELP O.20026344 O.37286706 O.49223070 http://www.streetinsider.com/Press+Releases/HELUS+Pharma+Propels+Therapeutic+Innovation+in+Mental+Health+and+Commences+Trading+on+Nasdaq/25801295.html <ul class="bwlistdisc"> <li> Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company </li> <li> Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP </li> <li> Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 </li> <li> Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been http://www.streetinsider.com/Press+Releases/HELUS+Pharma+Propels+Therapeutic+Innovation+in+Mental+Health+and+Commences+Trading+on+Nasdaq/25801295.html Mon, 05 Jan 2026 07:30:00 -0500 A.06822034 A.17150087 CYBN HELP HELP O.20026344 O.37286706 O.49223070 http://www.streetinsider.com/Press+Releases/HELUS+Pharma+Propels+Therapeutic+Innovation+in+Mental+Health+and+Commences+Trading+on+Nasdaq/25801295.html <ul class="bwlistdisc"> <li> Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company </li> <li> Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP </li> <li> Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 </li> <li> Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been http://www.streetinsider.com/Press+Releases/HELUS+Pharma+Propels+Therapeutic+Innovation+in+Mental+Health+and+Commences+Trading+on+Nasdaq/25801295.html Mon, 05 Jan 2026 07:30:00 -0500 A.06822034 A.17150087 CYBN HELP HELP O.20026344 O.37286706 O.49223070 http://www.streetinsider.com/Business+Wire/HELUS+Pharma+Propels+Therapeutic+Innovation+in+Mental+Health+and+Commences+Trading+on+Nasdaq/25801295.html <ul class="bwlistdisc"> <li> Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company </li> <li> Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP </li> <li> Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 </li> <li> Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been http://www.streetinsider.com/Business+Wire/HELUS+Pharma+Propels+Therapeutic+Innovation+in+Mental+Health+and+Commences+Trading+on+Nasdaq/25801295.html Mon, 05 Jan 2026 07:30:00 -0500 A.06822034 A.17150087 CYBN HELP HELP O.20026344 O.37286706 O.49223070 http://www.streetinsider.com/Business+Wire/HELUS+Pharma+Propels+Therapeutic+Innovation+in+Mental+Health+and+Commences+Trading+on+Nasdaq/25801295.html <ul class="bwlistdisc"> <li> Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company </li> <li> Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP </li> <li> Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 </li> <li> Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been http://www.streetinsider.com/Business+Wire/HELUS+Pharma+Propels+Therapeutic+Innovation+in+Mental+Health+and+Commences+Trading+on+Nasdaq/25801295.html Mon, 05 Jan 2026 07:30:00 -0500 A.06822034 A.17150087 CYBN HELP HELP O.20026344 O.37286706 O.49223070 http://www.streetinsider.com/Business+Wire/HELUS+Pharma+Propels+Therapeutic+Innovation+in+Mental+Health+and+Commences+Trading+on+Nasdaq/25801295.html <ul class="bwlistdisc"> <li> Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company </li> <li> Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP </li> <li> Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 </li> <li> Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been http://www.streetinsider.com/Business+Wire/HELUS+Pharma+Propels+Therapeutic+Innovation+in+Mental+Health+and+Commences+Trading+on+Nasdaq/25801295.html Mon, 05 Jan 2026 07:30:00 -0500 A.06822034 A.17150087 CYBN HELP HELP O.20026344 O.37286706 O.49223070 http://www.streetinsider.com/Business+Wire/HELUS+Pharma+Propels+Therapeutic+Innovation+in+Mental+Health+and+Commences+Trading+on+Nasdaq/25801295.html <ul class="bwlistdisc"> <li> Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company </li> <li> Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP </li> <li> Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 </li> <li> Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been http://www.streetinsider.com/Business+Wire/HELUS+Pharma+Propels+Therapeutic+Innovation+in+Mental+Health+and+Commences+Trading+on+Nasdaq/25801295.html Mon, 05 Jan 2026 07:30:00 -0500 A.06822034 A.17150087 CYBN HELP HELP O.20026344 O.37286706 O.49223070 http://www.streetinsider.com/Business+Wire/HELUS+Pharma+Propels+Therapeutic+Innovation+in+Mental+Health+and+Commences+Trading+on+Nasdaq/25801295.html <ul class="bwlistdisc"> <li> Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company </li> <li> Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP </li> <li> Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 </li> <li> Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been http://www.streetinsider.com/Business+Wire/HELUS+Pharma+Propels+Therapeutic+Innovation+in+Mental+Health+and+Commences+Trading+on+Nasdaq/25801295.html Mon, 05 Jan 2026 07:30:00 -0500 A.06822034 A.17150087 CYBN HELP HELP O.20026344 O.37286706 O.49223070 http://www.streetinsider.com/Business+Wire/HELUS+Pharma+Propels+Therapeutic+Innovation+in+Mental+Health+and+Commences+Trading+on+Nasdaq/25801295.html <ul class="bwlistdisc"> <li> Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company </li> <li> Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP </li> <li> Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 </li> <li> Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been http://www.streetinsider.com/Business+Wire/HELUS+Pharma+Propels+Therapeutic+Innovation+in+Mental+Health+and+Commences+Trading+on+Nasdaq/25801295.html Mon, 05 Jan 2026 07:30:00 -0500 A.06822034 A.17150087 CYBN HELP HELP O.20026344 O.37286706 O.49223070 http://www.streetinsider.com/Business+Wire/HELUS+Pharma+Propels+Therapeutic+Innovation+in+Mental+Health+and+Commences+Trading+on+Nasdaq/25801295.html <ul class="bwlistdisc"> <li> Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company </li> <li> Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP </li> <li> Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 </li> <li> Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been http://www.streetinsider.com/Business+Wire/HELUS+Pharma+Propels+Therapeutic+Innovation+in+Mental+Health+and+Commences+Trading+on+Nasdaq/25801295.html Mon, 05 Jan 2026 07:30:00 -0500 A.06822034 A.17150087 CYBN HELP HELP O.20026344 O.37286706 O.49223070 http://www.streetinsider.com/Business+Wire/HELUS+Pharma+Propels+Therapeutic+Innovation+in+Mental+Health+and+Commences+Trading+on+Nasdaq/25801295.html <ul class="bwlistdisc"> <li> Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company </li> <li> Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP </li> <li> Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 </li> <li> Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been http://www.streetinsider.com/Business+Wire/HELUS+Pharma+Propels+Therapeutic+Innovation+in+Mental+Health+and+Commences+Trading+on+Nasdaq/25801295.html Mon, 05 Jan 2026 07:30:00 -0500 A.06822034 A.17150087 CYBN HELP HELP O.20026344 O.37286706 O.49223070 http://www.streetinsider.com/SEC+Filings/Form++CERT+++++++CYBIN+INC.+++++++++++++++++++++++++++/25797014.html si-local-file:///var/storage/secattach/20260102/25797014.html http://www.streetinsider.com/SEC+Filings/Form++CERT+++++++CYBIN+INC.+++++++++++++++++++++++++++/25797014.html Fri, 02 Jan 2026 11:07:00 -0500 CYBN HELP O.37286706 http://www.streetinsider.com/SEC+Filings/Form++CERT+++++++CYBIN+INC.+++++++++++++++++++++++++++/25797014.html si-local-file:///var/storage/secattach/20260102/25797014.html http://www.streetinsider.com/SEC+Filings/Form++CERT+++++++CYBIN+INC.+++++++++++++++++++++++++++/25797014.html Fri, 02 Jan 2026 11:07:00 -0500 CYBN HELP O.37286706 http://www.streetinsider.com/SEC+Filings/Form++CERT+++++++CYBIN+INC.+++++++++++++++++++++++++++/25797014.html si-local-file:///var/storage/secattach/20260102/25797014.html http://www.streetinsider.com/SEC+Filings/Form++CERT+++++++CYBIN+INC.+++++++++++++++++++++++++++/25797014.html Fri, 02 Jan 2026 11:07:00 -0500 CYBN HELP O.37286706 http://www.streetinsider.com/SEC+Filings/Form++8-A12B+++++CYBIN+INC.+++++++++++++++++++++++++++/25795997.html si-local-file:///var/storage/secattach/20260102/25795997.html http://www.streetinsider.com/SEC+Filings/Form++8-A12B+++++CYBIN+INC.+++++++++++++++++++++++++++/25795997.html Fri, 02 Jan 2026 06:14:00 -0500 CYBN HELP O.37286706 http://www.streetinsider.com/SEC+Filings/Form++8-A12B+++++CYBIN+INC.+++++++++++++++++++++++++++/25795997.html si-local-file:///var/storage/secattach/20260102/25795997.html http://www.streetinsider.com/SEC+Filings/Form++8-A12B+++++CYBIN+INC.+++++++++++++++++++++++++++/25795997.html Fri, 02 Jan 2026 06:14:00 -0500 CYBN HELP O.37286706 http://www.streetinsider.com/SEC+Filings/Form++8-A12B+++++CYBIN+INC.+++++++++++++++++++++++++++/25795997.html si-local-file:///var/storage/secattach/20260102/25795997.html http://www.streetinsider.com/SEC+Filings/Form++8-A12B+++++CYBIN+INC.+++++++++++++++++++++++++++/25795997.html Fri, 02 Jan 2026 06:14:00 -0500 CYBN HELP O.37286706